Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)

April 24, 2025 8:23 AM EDT Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $329.00 price target on Amgen (NASDAQ: AMGN).The analyst commented: "Another ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login